2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145632
    Pemvidutide 2538014-94-5 99.40%
    Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
    Pemvidutide
  • HY-147062
    N-Acetyl-D-galactosamine-6-phosphate 18191-20-3 ≥99.0%
    N-acetyl-D-galactosamine 6-phosphate is a galactosamine phosphate that involved in galactose metabolism and phosphotransferase system (PTS). N-Acetyl-D-galactosamine-6-phosphate can be hydrolyze by NagA.
    N-Acetyl-D-galactosamine-6-phosphate
  • HY-147351
    GPR40 agonist 6 1798751-25-3 98.81%
    GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 (FFAR1 or GPR40) agonist with an EC50 of 0.058 μM.
    GPR40 agonist 6
  • HY-149048
    Adenosylhomocysteinase 9025-54-1
    Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients.
    Adenosylhomocysteinase
  • HY-149987
    LY3522348 2568608-48-8 98.30%
    KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation.
    LY3522348
  • HY-153213
    Org 274179-0 1421683-12-6 98.63%
    Org 274179-0 is a potent and allosteric antagonist of thyroid-stimulating hormone (TSH) receptor, with an IC50 of nanomolar concentration. Org 274179-0 completely inhibits TSH (and TSI)-mediated TSH receptor activation with little effect on the potency of TSH. Org 274179-0 can be used for the research of Graves' disease (GD).
    Org 274179-0
  • HY-156010
    PPARγ-IN-2 2682078-97-1 99.65%
    PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC50: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue.
    PPARγ-IN-2
  • HY-170404
    KF-52 3104612-74-7 98.94%
    KF-52 is a phosphofructokinase-1 (PFK1) inhibitor with an IC50 value of 2.1 μM. KF-52 significantly increases the ratio of oxygen consumption rate (OCR) to extracellular acidification rate (ECAR). KF-52 is applicable to research related to mitochondrial dysfunction.
    KF-52
  • HY-176136
    HNF4 agonist 1 99.37%
    HNF4 agonist 1 is a HNF4 agonist. HNF4 agonist 1 activates HNF4α and HNF4γ with EC50 values of 6 nM and 17 nM, respectively. HNF4 agonist 1 can be used in studies related to maturity-onset diabetes of the young type 1 (mody-1).
    HNF4 agonist 1
  • HY-B0380A
    Trimebutine maleate 34140-59-5 99.66%
    Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).
    Trimebutine maleate
  • HY-B0710R
    Betaine (Standard) 107-43-7 99.47%
    Betaine (Standard) is the analytical standard of Betaine. This product is intended for research and analytical applications. Betaine (Trimethylglycine) is a natural compound found in many foods and also an active methyl-donor which can maintain normal DNA methylation patterns[1,2]. Betaine is found ubiquitously in plants, animals, microorganisms, and rich dietary sources including seafood, spinach, and wheat bran. Betaine also acts as an osmolyte, to maintain the avian’s cellular water and ion balance to improve the avian’s capacity against heat stress via preventing dehydration and osmotic inactivation. It helps in maintaining the protective osmolytic activity, especially in heat-stressed birds. Betaine may promote various intestinal microbes against osmotic variations and thus improve microbial fermentation activity.
    Betaine (Standard)
  • HY-B1080A
    Tilorone 27591-97-5 99.80%
    Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels.
    Tilorone
  • HY-B1439B
    Lorglumide sodium 1021868-76-7 99.19%
    Lorglumide sodium salt (CR-1409 sodium salt) is a potent cholecystokinin (CCK) receptor antagonist.
    Lorglumide sodium
  • HY-E70052
    alpha-1,3-Galactosyltransferase (a1,3GalT) 128449-51-4
    alpha-1,3-Galactosyltransferase (a1,3GalT) (GGTA1) catalyzes the generation of the α-gal glycan via the transfer of a galactose (Gal) in α1-3 linkage, from a uridyl-diphosphate (UDP) donor onto the N-acetyllactosamine (Galβ1,4GlcNAc-R) of glycoproteins. alpha-1,3-Galactosyltransferase (a1,3GalT) is responsible for the synthesis of the α-galactose (α-Gal) epitope found in most mammalian species.
    alpha-1,3-Galactosyltransferase (a1,3GalT)
  • HY-E70075
    α-Glycerophosphate Dehydrogenase-Triosephosphate
    α-Glycerophosphate Dehydrogenase-Triosephosphate (GDH-TIM) is an enzyme mixture composed of glycerol phosphate dehydrogenase (GDH) and triphosphate isomerase (TIM). α-Glycerophosphate Dehydrogenase-Triosephosphate can be used to determine the activity of transketolase (TK) in hemolytic substances of red blood cells to evaluate vitamin B deficiency.
    α-Glycerophosphate Dehydrogenase-Triosephosphate
  • HY-N0157R
    Orotic acid (Standard) 65-86-1 99.51%
    Orotic acid (Standard) is the analytical standard of Orotic acid. This product is intended for research and analytical applications. Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats.
    Orotic acid (Standard)
  • HY-N0430A
    Coptisine Sulfate 1198398-71-8 99.37%
    Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease.
    Coptisine Sulfate
  • HY-N10549
    Gigantol 83088-28-2 99.79%
    Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury.
    Gigantol
  • HY-N9914R
    D-Psicose (Standard) 551-68-8 99.89%
    D-Psicose (Standard) is the analytical standard of D-Psicose (HY-N9914). This product is intended for research and analytical applications. D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease.
    D-Psicose (Standard)
  • HY-P1465A
    Human secretin TFA 98.62%
    Human secretin TFA is a 27-amino acid residue C-terminally amidated peptide, which acts on human secretin receptors.
    Human secretin TFA
Cat. No. Product Name / Synonyms Application Reactivity